ARCA Biopharma
ABIO

$3.14

2.55%

Market Cap: 45.6M

About: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Employees: 5

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0% less capital invested

Capital invested by funds: $12.7M [Q4 2023] → $12.7M (-$35.6K) [Q1 2024]

2.24% less ownership

Funds ownership: 51.89% [Q4 2023] → 49.65% (-2.24%) [Q1 2024]

8% less funds holding

Funds holding: 25 [Q4 2023] → 23 (-2) [Q1 2024]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ABIO.

See Analyst Rankings

Financial journalist opinion

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

Yesterday, the forgotten meme stocks of 2021 started picking up serious momentum. But unlike 2021, it didn't take much to see the reason behind GameStop's (NYSE: GME ) sudden surge.

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma, Inc. (the “Company”) (NasdaqCM: ABIO) and Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether th.

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed merger to Oruka Therapeutics.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma, Inc. (the “Company”) (NasdaqCM: ABIO) and Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether th.

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ: ABIO ) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases.

Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka

MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka

Arca Biopharma stock ($ABIO) soars on merger news

Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Oruka CEO comments on Arca Biopharma stock deal The combined company following completion of the all-stock transaction will operate as Oruka Therapeutics and trade under “ORKA” on Nasdaq.

Arca Biopharma stock ($ABIO) soars on merger news

ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ARCA biopharma, Inc. (NASDAQ: ABIO) and Oruka Therapeutics is fair to ARCA shareholders. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. Halper Sadeh encourages ARCA shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sa.

ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders

See News Rankings